Share Price and Basic Stock Data
Last Updated: October 16, 2025, 9:58 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Phyto Chem (India) Ltd operates in the agrochemicals and pesticides sector, primarily focusing on providing solutions to enhance agricultural productivity. In the fiscal year ending March 2025, the company reported a revenue of ₹14.08 Cr, a decline from ₹14.75 Cr in the previous fiscal year. Quarterly sales exhibited significant fluctuations, with the highest sales recorded at ₹12.47 Cr in September 2022, declining to ₹0.64 Cr by June 2023. The trailing twelve months (TTM) revenue stood at ₹10.98 Cr, indicating a challenging revenue environment. The operating profit margin (OPM) for the latest fiscal year was reported at -9.52%, reflecting ongoing operational challenges. Additionally, the company has recorded a cash conversion cycle of 615.87 days, which is considerably higher than typical industry standards, indicating potential inefficiencies in managing working capital. Overall, the revenue trends suggest volatility, underscoring the need for strategic adjustments to stabilize income streams.
Profitability and Efficiency Metrics
Phyto Chem’s profitability metrics reveal a concerning trend, with a net profit of -₹0.99 Cr for the fiscal year ending March 2025, following a similarly dismal performance of -₹3.33 Cr the previous year. The company has struggled with profitability, as reflected in its negative earnings per share (EPS) of -₹2.31 for the same period. The return on equity (ROE) stood at 14.6%, but this figure masks the underlying challenges since the company has reported net losses in consecutive years. The interest coverage ratio (ICR) of 0.61x indicates that the company may face difficulties in meeting its interest obligations, a risk factor for potential investors. Furthermore, the operating profit margin (OPM) has been negative for the last fiscal year, signaling operational inefficiencies. The fluctuating performance and negative net profit margins may raise concerns among stakeholders regarding the company’s ability to return to profitability in the near term.
Balance Sheet Strength and Financial Ratios
Phyto Chem’s balance sheet exhibits a total borrowing of ₹15.77 Cr against reserves of ₹2.09 Cr, indicating a high debt-to-equity ratio of 2.47x. This high leverage could pose risks in times of economic downturns or rising interest rates. The company’s current ratio of 1.25 suggests that it maintains adequate liquidity to cover its short-term obligations, though the quick ratio of 0.73 indicates potential liquidity pressures. The book value per share has declined to ₹14.85 from ₹17.11, reflecting a reduction in net worth amid operational losses. Additionally, the company’s return on capital employed (ROCE) has deteriorated to 3.27%, down from previous years, highlighting inefficiencies in utilizing capital for generating profits. The financial ratios indicate that while liquidity is manageable, the high debt levels and declining equity could affect long-term financial stability and growth prospects.
Shareholding Pattern and Investor Confidence
As of March 2025, Phyto Chem’s shareholding pattern reveals that promoters hold 40.40% of the company’s equity, while foreign institutional investors (FIIs) have not reported any holdings. Domestic institutional investors (DIIs) hold a minimal 0.19%, suggesting low institutional interest. The public shareholding stands at 54.78%, with a total of 7,245 shareholders, indicating a relatively broad base of retail investors. However, the absence of significant institutional investment could reflect concerns regarding the company’s operational performance and financial health. The stability in promoter holdings may provide some confidence in the company’s governance, yet the high public ownership coupled with low institutional interest could lead to volatility in share price movements. This pattern may influence investor sentiment, particularly in light of the company’s recent financial struggles.
Outlook, Risks, and Final Insight
Moving forward, Phyto Chem faces a dual challenge of improving its operational efficiency while managing its debt levels. If margins sustain their current trajectory, the company may find it difficult to attract new investments or maintain current shareholder confidence. The high cash conversion cycle and negative operating profit margins underscore the operational inefficiencies that must be addressed. Conversely, if the company can successfully implement strategies to enhance its revenue streams and optimize its working capital, there is potential for recovery. However, the reliance on debt financing poses a significant risk, particularly if economic conditions worsen. Overall, while there are opportunities for improvement, the path ahead requires careful navigation of financial and operational challenges in the competitive agrochemical sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Phyto Chem (India) Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Epigral Ltd | 7,343 Cr. | 1,702 | 2,243/1,502 | 17.0 | 441 | 0.35 % | 24.9 % | 22.3 % | 10.0 |
| Dharmaj Crop Guard Ltd | 1,024 Cr. | 303 | 391/165 | 19.6 | 117 | 0.00 % | 12.0 % | 9.28 % | 10.0 |
| Bhaskar Agrochemicals Ltd | 55.5 Cr. | 107 | 148/55.2 | 10.2 | 34.1 | 0.00 % | 21.3 % | 24.7 % | 10.0 |
| Bhagiradha Chemicals & Industries Ltd | 3,135 Cr. | 242 | 392/234 | 110 | 53.9 | 0.06 % | 7.44 % | 4.91 % | 1.00 |
| Best Agrolife Ltd | 789 Cr. | 334 | 670/244 | 11.5 | 320 | 0.90 % | 12.9 % | 9.95 % | 10.0 |
| Industry Average | 11,371.40 Cr | 1,525.30 | 34.62 | 440.43 | 0.41% | 15.21% | 19.87% | 7.25 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.41 | 12.47 | 7.88 | 5.00 | 0.64 | 7.21 | 6.51 | 0.45 | 4.61 | 4.37 | 3.65 | 1.46 | 1.50 |
| Expenses | 2.23 | 9.97 | 7.60 | 4.36 | 1.91 | 6.67 | 5.76 | 3.74 | 5.63 | 3.81 | 3.48 | 2.51 | 2.02 |
| Operating Profit | -0.82 | 2.50 | 0.28 | 0.64 | -1.27 | 0.54 | 0.75 | -3.29 | -1.02 | 0.56 | 0.17 | -1.05 | -0.52 |
| OPM % | -58.16% | 20.05% | 3.55% | 12.80% | -198.44% | 7.49% | 11.52% | -731.11% | -22.13% | 12.81% | 4.66% | -71.92% | -34.67% |
| Other Income | 0.00 | 0.03 | 0.06 | 0.07 | 0.15 | 0.01 | 0.07 | 2.09 | 0.01 | 0.01 | 1.94 | 0.51 | 0.40 |
| Interest | 0.50 | 0.46 | 0.48 | 0.66 | 0.56 | 0.63 | 0.44 | 0.42 | 0.38 | 0.38 | 0.52 | 0.57 | 0.33 |
| Depreciation | 0.10 | 0.10 | 0.10 | 0.10 | 0.08 | 0.08 | 0.10 | 0.09 | 0.08 | 0.08 | 0.08 | 0.08 | 0.09 |
| Profit before tax | -1.42 | 1.97 | -0.24 | -0.05 | -1.76 | -0.16 | 0.28 | -1.71 | -1.47 | 0.11 | 1.51 | -1.19 | -0.54 |
| Tax % | 10.56% | 0.00% | 29.17% | -360.00% | 0.00% | 0.00% | 0.00% | 0.00% | -0.68% | 0.00% | -0.66% | -3.36% | -9.26% |
| Net Profit | -1.57 | 1.98 | -0.31 | 0.12 | -1.76 | -0.16 | 0.29 | -1.71 | -1.47 | 0.11 | 1.52 | -1.16 | -0.48 |
| EPS in Rs | -3.65 | 4.60 | -0.72 | 0.28 | -4.09 | -0.37 | 0.67 | -3.98 | -3.42 | 0.26 | 3.53 | -2.70 | -1.12 |
Last Updated: August 20, 2025, 5:20 am
Below is a detailed analysis of the quarterly data for Phyto Chem (India) Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 1.50 Cr.. The value appears strong and on an upward trend. It has increased from 1.46 Cr. (Mar 2025) to 1.50 Cr., marking an increase of 0.04 Cr..
- For Expenses, as of Jun 2025, the value is 2.02 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2.51 Cr. (Mar 2025) to 2.02 Cr., marking a decrease of 0.49 Cr..
- For Operating Profit, as of Jun 2025, the value is -0.52 Cr.. The value appears strong and on an upward trend. It has increased from -1.05 Cr. (Mar 2025) to -0.52 Cr., marking an increase of 0.53 Cr..
- For OPM %, as of Jun 2025, the value is -34.67%. The value appears strong and on an upward trend. It has increased from -71.92% (Mar 2025) to -34.67%, marking an increase of 37.25%.
- For Other Income, as of Jun 2025, the value is 0.40 Cr.. The value appears to be declining and may need further review. It has decreased from 0.51 Cr. (Mar 2025) to 0.40 Cr., marking a decrease of 0.11 Cr..
- For Interest, as of Jun 2025, the value is 0.33 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.57 Cr. (Mar 2025) to 0.33 Cr., marking a decrease of 0.24 Cr..
- For Depreciation, as of Jun 2025, the value is 0.09 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.08 Cr. (Mar 2025) to 0.09 Cr., marking an increase of 0.01 Cr..
- For Profit before tax, as of Jun 2025, the value is -0.54 Cr.. The value appears strong and on an upward trend. It has increased from -1.19 Cr. (Mar 2025) to -0.54 Cr., marking an increase of 0.65 Cr..
- For Tax %, as of Jun 2025, the value is -9.26%. The value appears to be improving (decreasing) as expected. It has decreased from -3.36% (Mar 2025) to -9.26%, marking a decrease of 5.90%.
- For Net Profit, as of Jun 2025, the value is -0.48 Cr.. The value appears strong and on an upward trend. It has increased from -1.16 Cr. (Mar 2025) to -0.48 Cr., marking an increase of 0.68 Cr..
- For EPS in Rs, as of Jun 2025, the value is -1.12. The value appears strong and on an upward trend. It has increased from -2.70 (Mar 2025) to -1.12, marking an increase of 1.58.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: August 23, 2025, 2:16 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 29.29 | 40.92 | 21.77 | 44.45 | 58.90 | 59.11 | 44.22 | 44.49 | 23.12 | 26.76 | 14.75 | 14.08 | 10.98 |
| Expenses | 26.32 | 38.27 | 20.24 | 41.58 | 56.75 | 56.68 | 42.30 | 42.28 | 21.70 | 24.16 | 18.02 | 15.42 | 11.82 |
| Operating Profit | 2.97 | 2.65 | 1.53 | 2.87 | 2.15 | 2.43 | 1.92 | 2.21 | 1.42 | 2.60 | -3.27 | -1.34 | -0.84 |
| OPM % | 10.14% | 6.48% | 7.03% | 6.46% | 3.65% | 4.11% | 4.34% | 4.97% | 6.14% | 9.72% | -22.17% | -9.52% | -7.65% |
| Other Income | -0.06 | 0.12 | 0.68 | 0.27 | 1.55 | 0.98 | 1.38 | 0.80 | 1.29 | 0.16 | 2.32 | 2.47 | 2.86 |
| Interest | 1.63 | 1.64 | 1.72 | 1.67 | 2.13 | 2.10 | 2.47 | 2.12 | 2.10 | 2.10 | 2.05 | 1.84 | 1.80 |
| Depreciation | 0.35 | 0.32 | 0.31 | 0.31 | 0.36 | 0.40 | 0.41 | 0.43 | 0.41 | 0.40 | 0.34 | 0.34 | 0.33 |
| Profit before tax | 0.93 | 0.81 | 0.18 | 1.16 | 1.21 | 0.91 | 0.42 | 0.46 | 0.20 | 0.26 | -3.34 | -1.05 | -0.11 |
| Tax % | 34.41% | 34.57% | 38.89% | 26.72% | 23.97% | 19.78% | -4.76% | -6.52% | -15.00% | 15.38% | -0.30% | -5.71% | |
| Net Profit | 0.61 | 0.54 | 0.12 | 0.85 | 0.92 | 0.73 | 0.45 | 0.49 | 0.23 | 0.22 | -3.33 | -0.99 | -0.01 |
| EPS in Rs | 1.42 | 1.26 | 0.28 | 1.98 | 2.14 | 1.70 | 1.05 | 1.14 | 0.53 | 0.51 | -7.74 | -2.30 | -0.03 |
| Dividend Payout % | 70.49% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -11.48% | -77.78% | 608.33% | 8.24% | -20.65% | -38.36% | 8.89% | -53.06% | -4.35% | -1613.64% | 70.27% |
| Change in YoY Net Profit Growth (%) | 0.00% | -66.30% | 686.11% | -600.10% | -28.89% | -17.70% | 47.25% | -61.95% | 48.71% | -1609.29% | 1683.91% |
Phyto Chem (India) Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -10% |
| 5 Years: | -20% |
| 3 Years: | -15% |
| TTM: | -42% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 100% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | 4% |
| 3 Years: | 15% |
| 1 Year: | -5% |
| Return on Equity | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | -8% |
| 3 Years: | -16% |
| Last Year: | -14% |
Last Updated: September 5, 2025, 12:30 pm
Balance Sheet
Last Updated: October 10, 2025, 2:45 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.30 | 4.30 | 4.30 | 4.30 | 4.30 | 4.30 | 4.30 | 4.30 | 4.30 | 4.30 | 4.30 | 4.30 |
| Reserves | 3.12 | 3.48 | 3.60 | 4.00 | 4.52 | 5.12 | 5.55 | 5.88 | 6.15 | 6.31 | 3.06 | 2.09 |
| Borrowings | 14.22 | 16.00 | 16.04 | 18.46 | 18.55 | 22.08 | 22.98 | 21.37 | 21.23 | 19.47 | 18.19 | 15.77 |
| Other Liabilities | 10.53 | 11.92 | 5.63 | 15.24 | 30.31 | 41.46 | 34.87 | 13.91 | 6.78 | 9.94 | 6.16 | 5.72 |
| Total Liabilities | 32.17 | 35.70 | 29.57 | 42.00 | 57.68 | 72.96 | 67.70 | 45.46 | 38.46 | 40.02 | 31.71 | 27.88 |
| Fixed Assets | 4.21 | 3.68 | 3.50 | 3.25 | 4.10 | 4.18 | 4.67 | 3.43 | 3.13 | 2.75 | 2.74 | 2.39 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.09 | 0.45 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.32 | 0.32 | 0.32 | 0.24 | 0.25 | 0.12 | 0.11 | 0.16 | 0.17 | 0.07 | 0.08 | 0.05 |
| Other Assets | 27.64 | 31.70 | 25.75 | 38.51 | 53.24 | 68.21 | 62.92 | 41.87 | 35.16 | 37.20 | 28.89 | 25.44 |
| Total Assets | 32.17 | 35.70 | 29.57 | 42.00 | 57.68 | 72.96 | 67.70 | 45.46 | 38.46 | 40.02 | 31.71 | 27.88 |
Below is a detailed analysis of the balance sheet data for Phyto Chem (India) Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 4.30 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 4.30 Cr..
- For Reserves, as of Mar 2025, the value is 2.09 Cr.. The value appears to be declining and may need further review. It has decreased from 3.06 Cr. (Mar 2024) to 2.09 Cr., marking a decrease of 0.97 Cr..
- For Borrowings, as of Mar 2025, the value is 15.77 Cr.. The value appears to be improving (decreasing). However, Borrowings exceed Reserves, which may signal higher financial risk. It has decreased from 18.19 Cr. (Mar 2024) to 15.77 Cr., marking a decrease of 2.42 Cr..
- For Other Liabilities, as of Mar 2025, the value is 5.72 Cr.. The value appears to be improving (decreasing). It has decreased from 6.16 Cr. (Mar 2024) to 5.72 Cr., marking a decrease of 0.44 Cr..
- For Total Liabilities, as of Mar 2025, the value is 27.88 Cr.. The value appears to be improving (decreasing). It has decreased from 31.71 Cr. (Mar 2024) to 27.88 Cr., marking a decrease of 3.83 Cr..
- For Fixed Assets, as of Mar 2025, the value is 2.39 Cr.. The value appears to be declining and may need further review. It has decreased from 2.74 Cr. (Mar 2024) to 2.39 Cr., marking a decrease of 0.35 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 0.05 Cr.. The value appears to be declining and may need further review. It has decreased from 0.08 Cr. (Mar 2024) to 0.05 Cr., marking a decrease of 0.03 Cr..
- For Other Assets, as of Mar 2025, the value is 25.44 Cr.. The value appears to be declining and may need further review. It has decreased from 28.89 Cr. (Mar 2024) to 25.44 Cr., marking a decrease of 3.45 Cr..
- For Total Assets, as of Mar 2025, the value is 27.88 Cr.. The value appears to be declining and may need further review. It has decreased from 31.71 Cr. (Mar 2024) to 27.88 Cr., marking a decrease of 3.83 Cr..
However, the Borrowings (15.77 Cr.) are higher than the Reserves (2.09 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -11.25 | -13.35 | -14.51 | -15.59 | -16.40 | -19.65 | -21.06 | -19.16 | -19.81 | -16.87 | -21.46 | -17.11 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 209.73 | 155.83 | 247.97 | 212.84 | 234.37 | 306.89 | 360.30 | 182.87 | 317.01 | 275.66 | 388.26 | 369.41 |
| Inventory Days | 167.93 | 159.73 | 260.64 | 133.35 | 115.59 | 128.58 | 182.77 | 172.49 | 342.41 | 314.83 | 373.42 | 338.21 |
| Days Payable | 99.24 | 113.43 | 86.08 | 135.72 | 176.25 | 283.01 | 338.07 | 110.32 | 41.10 | 122.87 | 91.09 | 91.75 |
| Cash Conversion Cycle | 278.42 | 202.12 | 422.53 | 210.47 | 173.71 | 152.46 | 205.00 | 245.04 | 618.32 | 467.62 | 670.59 | 615.87 |
| Working Capital Days | 59.32 | 48.26 | 103.95 | 53.62 | 43.75 | 45.14 | 69.58 | 85.08 | 155.35 | 150.45 | 161.34 | 129.88 |
| ROCE % | 13.06% | 12.02% | 7.75% | 11.16% | 12.34% | 10.16% | 8.98% | 6.96% | 7.28% | 7.55% | -4.93% | 3.27% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -2.31 | -7.75 | 0.52 | 0.53 | 1.15 |
| Diluted EPS (Rs.) | -2.31 | -7.75 | 0.52 | 0.53 | 1.15 |
| Cash EPS (Rs.) | -1.52 | -6.95 | 1.44 | 1.49 | 2.14 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 14.85 | 17.11 | 24.68 | 24.31 | 23.68 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 14.85 | 17.11 | 24.68 | 24.31 | 23.68 |
| Revenue From Operations / Share (Rs.) | 32.74 | 34.44 | 62.23 | 53.76 | 103.46 |
| PBDIT / Share (Rs.) | 2.62 | -2.20 | 6.42 | 6.28 | 7.00 |
| PBIT / Share (Rs.) | 1.84 | -3.00 | 5.50 | 5.33 | 6.01 |
| PBT / Share (Rs.) | -2.44 | -7.76 | 0.61 | 0.45 | 1.08 |
| Net Profit / Share (Rs.) | -2.31 | -7.75 | 0.51 | 0.53 | 1.15 |
| PBDIT Margin (%) | 8.01 | -6.39 | 10.31 | 11.68 | 6.76 |
| PBIT Margin (%) | 5.62 | -8.70 | 8.83 | 9.91 | 5.80 |
| PBT Margin (%) | -7.44 | -22.54 | 0.98 | 0.85 | 1.04 |
| Net Profit Margin (%) | -7.04 | -22.48 | 0.83 | 0.99 | 1.10 |
| Return on Networth / Equity (%) | -15.52 | -45.25 | 2.09 | 2.19 | 4.84 |
| Return on Capital Employeed (%) | 9.82 | -12.59 | 16.06 | 16.83 | 17.57 |
| Return On Assets (%) | -3.55 | -10.50 | 0.55 | 0.60 | 1.09 |
| Long Term Debt / Equity (X) | 0.13 | 0.23 | 0.26 | 0.22 | 0.35 |
| Total Debt / Equity (X) | 2.47 | 2.47 | 1.83 | 1.88 | 1.89 |
| Asset Turnover Ratio (%) | 0.47 | 0.41 | 0.68 | 0.55 | 0.78 |
| Current Ratio (X) | 1.25 | 1.31 | 1.44 | 1.40 | 1.35 |
| Quick Ratio (X) | 0.73 | 0.75 | 0.85 | 0.88 | 0.81 |
| Inventory Turnover Ratio (X) | 0.95 | 0.75 | 1.31 | 0.94 | 2.24 |
| Interest Coverage Ratio (X) | 0.61 | -0.46 | 1.31 | 1.29 | 1.42 |
| Interest Coverage Ratio (Post Tax) (X) | 0.46 | -0.62 | 1.11 | 1.11 | 1.23 |
| Enterprise Value (Cr.) | 28.18 | 31.77 | 33.51 | 28.18 | 26.50 |
| EV / Net Operating Revenue (X) | 2.00 | 2.15 | 1.25 | 1.22 | 0.59 |
| EV / EBITDA (X) | 24.97 | -33.54 | 12.14 | 10.43 | 8.81 |
| MarketCap / Net Operating Revenue (X) | 0.88 | 0.92 | 0.52 | 0.37 | 0.16 |
| Price / BV (X) | 1.95 | 1.87 | 1.33 | 0.83 | 0.72 |
| Price / Net Operating Revenue (X) | 0.88 | 0.92 | 0.52 | 0.37 | 0.16 |
| EarningsYield | -0.07 | -0.24 | 0.01 | 0.02 | 0.06 |
After reviewing the key financial ratios for Phyto Chem (India) Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -2.31. This value is below the healthy minimum of 5. It has increased from -7.75 (Mar 24) to -2.31, marking an increase of 5.44.
- For Diluted EPS (Rs.), as of Mar 25, the value is -2.31. This value is below the healthy minimum of 5. It has increased from -7.75 (Mar 24) to -2.31, marking an increase of 5.44.
- For Cash EPS (Rs.), as of Mar 25, the value is -1.52. This value is below the healthy minimum of 3. It has increased from -6.95 (Mar 24) to -1.52, marking an increase of 5.43.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 14.85. It has decreased from 17.11 (Mar 24) to 14.85, marking a decrease of 2.26.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 14.85. It has decreased from 17.11 (Mar 24) to 14.85, marking a decrease of 2.26.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 32.74. It has decreased from 34.44 (Mar 24) to 32.74, marking a decrease of 1.70.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 2.62. This value is within the healthy range. It has increased from -2.20 (Mar 24) to 2.62, marking an increase of 4.82.
- For PBIT / Share (Rs.), as of Mar 25, the value is 1.84. This value is within the healthy range. It has increased from -3.00 (Mar 24) to 1.84, marking an increase of 4.84.
- For PBT / Share (Rs.), as of Mar 25, the value is -2.44. This value is below the healthy minimum of 0. It has increased from -7.76 (Mar 24) to -2.44, marking an increase of 5.32.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -2.31. This value is below the healthy minimum of 2. It has increased from -7.75 (Mar 24) to -2.31, marking an increase of 5.44.
- For PBDIT Margin (%), as of Mar 25, the value is 8.01. This value is below the healthy minimum of 10. It has increased from -6.39 (Mar 24) to 8.01, marking an increase of 14.40.
- For PBIT Margin (%), as of Mar 25, the value is 5.62. This value is below the healthy minimum of 10. It has increased from -8.70 (Mar 24) to 5.62, marking an increase of 14.32.
- For PBT Margin (%), as of Mar 25, the value is -7.44. This value is below the healthy minimum of 10. It has increased from -22.54 (Mar 24) to -7.44, marking an increase of 15.10.
- For Net Profit Margin (%), as of Mar 25, the value is -7.04. This value is below the healthy minimum of 5. It has increased from -22.48 (Mar 24) to -7.04, marking an increase of 15.44.
- For Return on Networth / Equity (%), as of Mar 25, the value is -15.52. This value is below the healthy minimum of 15. It has increased from -45.25 (Mar 24) to -15.52, marking an increase of 29.73.
- For Return on Capital Employeed (%), as of Mar 25, the value is 9.82. This value is below the healthy minimum of 10. It has increased from -12.59 (Mar 24) to 9.82, marking an increase of 22.41.
- For Return On Assets (%), as of Mar 25, the value is -3.55. This value is below the healthy minimum of 5. It has increased from -10.50 (Mar 24) to -3.55, marking an increase of 6.95.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.13. This value is below the healthy minimum of 0.2. It has decreased from 0.23 (Mar 24) to 0.13, marking a decrease of 0.10.
- For Total Debt / Equity (X), as of Mar 25, the value is 2.47. This value exceeds the healthy maximum of 1. There is no change compared to the previous period (Mar 24) which recorded 2.47.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.47. It has increased from 0.41 (Mar 24) to 0.47, marking an increase of 0.06.
- For Current Ratio (X), as of Mar 25, the value is 1.25. This value is below the healthy minimum of 1.5. It has decreased from 1.31 (Mar 24) to 1.25, marking a decrease of 0.06.
- For Quick Ratio (X), as of Mar 25, the value is 0.73. This value is below the healthy minimum of 1. It has decreased from 0.75 (Mar 24) to 0.73, marking a decrease of 0.02.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.95. This value is below the healthy minimum of 4. It has increased from 0.75 (Mar 24) to 0.95, marking an increase of 0.20.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 0.61. This value is below the healthy minimum of 3. It has increased from -0.46 (Mar 24) to 0.61, marking an increase of 1.07.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.46. This value is below the healthy minimum of 3. It has increased from -0.62 (Mar 24) to 0.46, marking an increase of 1.08.
- For Enterprise Value (Cr.), as of Mar 25, the value is 28.18. It has decreased from 31.77 (Mar 24) to 28.18, marking a decrease of 3.59.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.00. This value is within the healthy range. It has decreased from 2.15 (Mar 24) to 2.00, marking a decrease of 0.15.
- For EV / EBITDA (X), as of Mar 25, the value is 24.97. This value exceeds the healthy maximum of 15. It has increased from -33.54 (Mar 24) to 24.97, marking an increase of 58.51.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.88. This value is below the healthy minimum of 1. It has decreased from 0.92 (Mar 24) to 0.88, marking a decrease of 0.04.
- For Price / BV (X), as of Mar 25, the value is 1.95. This value is within the healthy range. It has increased from 1.87 (Mar 24) to 1.95, marking an increase of 0.08.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.88. This value is below the healthy minimum of 1. It has decreased from 0.92 (Mar 24) to 0.88, marking a decrease of 0.04.
- For EarningsYield, as of Mar 25, the value is -0.07. This value is below the healthy minimum of 5. It has increased from -0.24 (Mar 24) to -0.07, marking an increase of 0.17.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Phyto Chem (India) Ltd:
- Net Profit Margin: -7.04%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 9.82% (Industry Average ROCE: 15.21%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -15.52% (Industry Average ROE: 19.87%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0.46
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.73
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 34.62)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 2.47
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -7.04%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Agro Chemicals/Pesticides | Survey No.628, Temple Street, Sangareddy Dist. Telangana 502313 | investorsrelations@phytochemindia.com http://www.phytochemindia.com |
| Management | |
|---|---|
| Name | Position Held |
| Dr. P Sreemannarayana | Chairman |
| Mr. Y Nayudamma | Managing Director |
| Mr. Y Janaki Ramaiah | Executive Director |
| Mr. P Anjaneyulu | Director |
| Dr. Y Venkateswarlu | Director |
| Mr. S Y Sampath Kumar | Independent Director |
| Dr. G S R Anjaneyulu | Independent Director |
| Dr. M Sreerama Murthy | Independent Director |
| Mrs. G Vijitha | Independent Director |
| Mr. N Nagendra Naidu | Independent Director |
| Mr. K Srinivasa Rao | Alternate Director |
FAQ
What is the intrinsic value of Phyto Chem (India) Ltd?
Phyto Chem (India) Ltd's intrinsic value (as of 17 October 2025) is 26.63 which is 3.62% higher the current market price of 25.70, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 11.0 Cr. market cap, FY2025-2026 high/low of 42.9/24.5, reserves of ₹2.09 Cr, and liabilities of 27.88 Cr.
What is the Market Cap of Phyto Chem (India) Ltd?
The Market Cap of Phyto Chem (India) Ltd is 11.0 Cr..
What is the current Stock Price of Phyto Chem (India) Ltd as on 17 October 2025?
The current stock price of Phyto Chem (India) Ltd as on 17 October 2025 is 25.7.
What is the High / Low of Phyto Chem (India) Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Phyto Chem (India) Ltd stocks is 42.9/24.5.
What is the Stock P/E of Phyto Chem (India) Ltd?
The Stock P/E of Phyto Chem (India) Ltd is .
What is the Book Value of Phyto Chem (India) Ltd?
The Book Value of Phyto Chem (India) Ltd is 14.9.
What is the Dividend Yield of Phyto Chem (India) Ltd?
The Dividend Yield of Phyto Chem (India) Ltd is 0.00 %.
What is the ROCE of Phyto Chem (India) Ltd?
The ROCE of Phyto Chem (India) Ltd is 3.27 %.
What is the ROE of Phyto Chem (India) Ltd?
The ROE of Phyto Chem (India) Ltd is 14.6 %.
What is the Face Value of Phyto Chem (India) Ltd?
The Face Value of Phyto Chem (India) Ltd is 10.0.